95 related articles for article (PubMed ID: 2123505)
1. [Urine determination of CEA, CA50 and TPA as tumor markers in bladder neoplasms].
Morote J; López-Pacios MA; Encabo G; de Torres JA
Med Clin (Barc); 1990 Jun; 95(3):119. PubMed ID: 2123505
[No Abstract] [Full Text] [Related]
2. Urinary evaluation of tumor-associated antigens in urothelial bladder tumors.
Piana P; Casetta G; Cavallini A; Piantino P; Tizzani A
Prog Clin Biol Res; 1991; 370():179-84. PubMed ID: 1924448
[No Abstract] [Full Text] [Related]
3. [Blood and urinary values of CEA and CA 19-9 in patients with bladder carcinoma].
Cicigoi A; Rocca Rossetti S; Piantino P; Cerchier A
Minerva Med; 1986 Nov; 77(42-43):1983-7. PubMed ID: 3464851
[TBL] [Abstract][Full Text] [Related]
4. Urine carcinoembryonic antigen levels are more useful than serum levels for early detection of Bilharzial and non-Bilharzial urinary bladder carcinoma: observations of 43 Egyptian cases.
Saied GM; El-Metenawy WH; Elwan MS; Dessouki NR
World J Surg Oncol; 2007 Jan; 5():4. PubMed ID: 17224047
[TBL] [Abstract][Full Text] [Related]
5. Urinary levels of tumour associated antigens (CA 19-9, TPA and CEA) in patients with neoplastic and non-neoplastic urothelial abnormalities.
Casetta G; Piana P; Cavallini A; Vottero M; Tizzani A
Br J Urol; 1993 Jul; 72(1):60-4. PubMed ID: 8149183
[TBL] [Abstract][Full Text] [Related]
6. Comparison between tissue antigen analysis and plasma determinations for TPA and CEA in transitional cell carcinomas and in tumorfree urothelium of the urinary bladder.
Vogel J; Oehr P; Maisey R; Adolphs HD
Cancer Detect Prev; 1988; 11(3-6):389-96. PubMed ID: 2455597
[TBL] [Abstract][Full Text] [Related]
7. Clinical value of determination of urokinase-type plasminogen activator antigen in plasma for detection of colorectal cancer: comparison with circulating tumor-associated antigens CA 19-9 and carcinoembryonic antigen.
Huber K; Kirchheimer JC; Sedlmayer A; Bell C; Ermler D; Binder BR
Cancer Res; 1993 Apr; 53(8):1788-93. PubMed ID: 8467497
[TBL] [Abstract][Full Text] [Related]
8. Simultaneous determination of urinary CEA, ferritin and TPA in Egyptian bladder cancer patients.
Halim AB; el-Ahmady O; Hamza S; Aboul-Ela M; Oehr P
Int J Biol Markers; 1992; 7(4):234-9. PubMed ID: 1491179
[TBL] [Abstract][Full Text] [Related]
9. Tumor markers (CEA, TPA and CA 19-9) in urine of bladder cancer patients.
Tizzani A; Cassetta G; Cicigoi A; Piana P; Cerchier A; Pecchio F; Piantino P
Int J Biol Markers; 1987; 2(2):121-4. PubMed ID: 3482861
[TBL] [Abstract][Full Text] [Related]
10. [Urinary BTA-TRAK in the follow-up of superficial transitional-cell bladder carcinoma].
Fernández Gómez JM; García Rodríguez J; Escaf Barmadah S; Raigoso P; Rodríguez Martínez JJ; Allende MT; Casasola Chamorro J; Rodríguez Faba O; Martín Benito JL; Regadera Sejas FJ
Arch Esp Urol; 2002; 55(1):41-9. PubMed ID: 11957750
[TBL] [Abstract][Full Text] [Related]
11. Immunocyt test improves the diagnostic accuracy of urinary cytology: results of a French multicenter study.
Pfister C; Chautard D; Devonec M; Perrin P; Chopin D; Rischmann P; Bouchot O; Beurton D; Coulange C; Rambeaud JJ
J Urol; 2003 Mar; 169(3):921-4. PubMed ID: 12576813
[TBL] [Abstract][Full Text] [Related]
12. Chemiluminometric determination of tissue polypeptide antigen (TPA), cancer antigen 15-3 (CA 15-3), carcinoembryonic antigen (CEA) in comparison with vascular endothelial growth factor (VEGF) in follow-up of breast cancer.
Findeisen R; Albrecht S; Richter B; Deutschmann K; Zimmermann T; Distler W
Luminescence; 2000; 15(5):283-9. PubMed ID: 11038485
[TBL] [Abstract][Full Text] [Related]
13. [Clinical evaluation of a combination assay of CEA, CA-19-9 and TPA in patients with colorectal cancer].
Nishida O; Shiroto H; Satoh N; Nakajima Y; Manabe K; Kondoh Y; Sano F; Uchino J
Gan No Rinsho; 1988 Aug; 34(9):1096-100. PubMed ID: 3172515
[TBL] [Abstract][Full Text] [Related]
14. The tumor markers CEA, TPA and CA 19-9 in gastric cancer.
Putzki H; Reichert B; Jablonski M; Heymann H
Dtsch Z Verdau Stoffwechselkr; 1988; 48(3-4):145-8. PubMed ID: 3234297
[TBL] [Abstract][Full Text] [Related]
15. Four bladder tumor markers have a disappointingly low sensitivity for small size and low grade recurrence.
Boman H; Hedelin H; Holmäng S
J Urol; 2002 Jan; 167(1):80-3. PubMed ID: 11743280
[TBL] [Abstract][Full Text] [Related]
16. Considerations on the use of urine markers for bladder cancer.
van Rhijn BW
Eur Urol; 2008 May; 53(5):880-1. PubMed ID: 18222604
[No Abstract] [Full Text] [Related]
17. Serum tumor markers in colorectal cancer staging, grading, and follow-up.
Plebani M; De Paoli M; Basso D; Roveroni G; Giacomini A; Galeotti F; Corsini A
J Surg Oncol; 1996 Aug; 62(4):239-44. PubMed ID: 8691835
[TBL] [Abstract][Full Text] [Related]
18. [Clinicopathological study of urinary bladder tumors. Clinical evaluation of immunohistochemistry in urine cytology].
Nagata Y; Kinoshita H; Kawamura N; Sasadaira S
Hinyokika Kiyo; 1985 Nov; 31(11):1931-7. PubMed ID: 4091136
[TBL] [Abstract][Full Text] [Related]
19. [Tissue plasminogen activator in urine of patients with prostatic carcinoma and benign prostatic hyperplasia].
Zietek Z; Iwan-Zietek I; Kotschy M; Wolski Z; Kulwas A; Białkowska A
Pol Merkur Lekarski; 1997 Apr; 2(10):266-7. PubMed ID: 9377662
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic value of urine cytology and urine carcinoembryonic antigen (CEA) level in the distinction between bladder cancer and urinary tract infection.
Gajda M; Tyloch F; Jóźwicki W; Tyloch J; Sujkowska R; Skok Z
Int J Occup Med Environ Health; 1995; 8(2):103-8. PubMed ID: 7582848
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
